lapatinib has been researched along with bms201038 in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (bms201038) | Trials (bms201038) | Recent Studies (post-2010) (bms201038) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 128 | 13 | 106 |
Protein | Taxonomy | lapatinib (IC50) | bms201038 (IC50) |
---|---|---|---|
Delta-type opioid receptor | Mus musculus (house mouse) | 0.0008 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.0056 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Combrinck, JM; de Sousa, ACC; Egan, TJ; Maepa, K | 1 |
1 other study(ies) available for lapatinib and bms201038
Article | Year |
---|---|
Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites.
Topics: Antimalarials; Benzimidazoles; Binding Sites; Chloroquine; Drug Repositioning; Drug Resistance; Erythrocytes; Hemeproteins; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Lapatinib; Molecular Docking Simulation; Plasmodium falciparum; Pyrimethamine; Pyrimidines; Thermodynamics | 2020 |